ONCT Projected Dividend Yield
Oncternal Therapeutics Inc ( NASDAQ : ONCT )Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Co.'s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. 21 YEAR PERFORMANCE RESULTS |
ONCT Dividend History Detail ONCT Dividend News ONCT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |